These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 31003189

  • 21. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y.
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [Abstract] [Full Text] [Related]

  • 22. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
    Nasser Y, Labetoulle R, Harzallah I, Berger AE, Roblin X, Paul S.
    Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
    [Abstract] [Full Text] [Related]

  • 23. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease.
    Guiotto C, Daperno M, Frigerio F, Vizzini M, Cerruti R, Ercole E, Cosimato M, Lavagna A, Germano L, Migliardi M, Rocca R.
    Dig Liver Dis; 2016 Feb; 48(2):138-43. PubMed ID: 26614644
    [Abstract] [Full Text] [Related]

  • 24. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
    Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA.
    Inflamm Bowel Dis; 2021 Aug 19; 27(9):1443-1451. PubMed ID: 33252119
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
    Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT.
    Clin Gastroenterol Hepatol; 2015 Jun 19; 13(6):1118-24.e3. PubMed ID: 25562796
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, Lee S, Kim S, Eliakim R, Chowers Y.
    Gut; 2016 Jul 19; 65(7):1132-8. PubMed ID: 25897019
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
    Scaldaferri F, D'Ambrosio D, Holleran G, Poscia A, Petito V, Lopetuso L, Graziani C, Laterza L, Pistone MT, Pecere S, Currò D, Gaetani E, Armuzzi A, Papa A, Cammarota G, Gasbarrini A.
    PLoS One; 2017 Jul 19; 12(10):e0186575. PubMed ID: 29073159
    [Abstract] [Full Text] [Related]

  • 36. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.
    Imaeda H, Andoh A, Fujiyama Y.
    J Gastroenterol; 2012 Feb 19; 47(2):136-43. PubMed ID: 21953314
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.
    Raffáč Š, Gombošová L, Gabzdilová J, Novotná L, Šajtyová K, Pekárová T, Kopolovets I, Tóth Š.
    Neuro Endocrinol Lett; 2017 Nov 19; 38(Suppl1):5-9. PubMed ID: 29200248
    [Abstract] [Full Text] [Related]

  • 40. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B, Glidai Y, Yavzori M, Picard O, Fudim E, Lahad A, Haberman Y, Shouval DS, Weintraub I, Eliakim R, Ben-Horin S, Weiss B.
    J Pediatr Gastroenterol Nutr; 2018 Oct 19; 67(4):507-512. PubMed ID: 29901557
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.